<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01096030</url>
  </required_header>
  <id_info>
    <org_study_id>14996</org_study_id>
    <nct_id>NCT01096030</nct_id>
  </id_info>
  <brief_title>Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors</brief_title>
  <official_title>Uncontrolled, Open-label, Non-randomized, Phase 1 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be an uncontrolled, open-label, non-randomized, phase I study. The primary
      objectives of this study are to define the pharmacokinetics (PK) and to evaluate the safety
      and tolerability of Regorafenib administered orally as a single agent in Chinese patients
      with advanced solid tumors. The secondary objectives are to evaluate tumor response of
      patients treated with Regorafenib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics as measured by cmax and AUC</measure>
    <time_frame>Cycle 0, Day 1-5,Cycle 1 Day 1,8,15,21,Cycle 2 Day 1,Modified Dosing Cycle Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Event collection</measure>
    <time_frame>every 1-2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate</measure>
    <time_frame>Every 8 weeks for the first 6 cycles, afterwards every 12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory biomarker analysis</measure>
    <time_frame>Screening, Cycle 0 or 1</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Regorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib (Stivarga, BAY73-4506)</intervention_name>
    <description>160 mg oral once daily BAY 73-4506 for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off)</description>
    <arm_group_label>Regorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female Chinese subjects &gt;/- 18 years

          -  Advanced, histologically or cytologically confirmed solid tumors

          -  Subjects malignancies must be refractory to standard treatment or have no standard
             therapy available, or the subject actively refused any treatment that would be
             regarded standard, and/or if, in the judgment of the investigator or his/her
             designated associate(s), experimental treatment is clinically and ethically
             acceptable.

          -  Eastern Cooperative Oncology Group performance status (ECOG-PS) 0-1;

          -  Adequate bone marrow, liver and renal function

          -  Life expectancy of at least 3 months

        Exclusion Criteria:

          -  Unstable/uncontrolled cardiac disease

          -  History of arterial or venous thrombotic or embolic events

          -  Malabsorption condition

          -  Severe renal impairment; persistent proteinuria &gt;/= Grade 3

          -  Symptomatic metastatic brain or meningeal tumors

          -  Clinically significant bleeding &gt;/=Grade 3 within 30 days before start of study
             medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Shatin</city>
        <state>N.T</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <last_update_submitted>November 18, 2013</last_update_submitted>
  <last_update_submitted_qc>November 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Regorafenib</keyword>
  <keyword>Advanced</keyword>
  <keyword>Refractory solid tumors</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

